Can Patients With Atrial Fibrillation Be Optimally Risk Stratified for Stroke and Thromboembolism?

To the Editor:

Atrial fibrillation (AF) has repeatedly been shown to be associated with a substantial risk of stroke, but this risk is not consistent across all populations. Identifying patients at greatest risk of this (sometimes disastrous) complication is problematic. Therefore, the development of various stroke risk stratification models based on data from large clinical studies has proved useful in targeting anticoagulation to those at moderate-high risk of stroke, whereas those considered at low risk are generally offered aspirin as an alternative, despite the limited evidence for aspirin in this setting.1 These stratification models based on data from large clinical studies have consistently demonstrated that their study cohort were receiving warfarin or ximelagatran may influence the thromboembolic event rates. Also, their estimations of stroke risk could also have been anticipated from pre-existing literature, where validation studies (usually in nonanticoagulated populations) have consistently demonstrated that model is ideal and all frequently underestimate stroke risk.2,3 Indeed, the c statistic (assessing the predictive accuracy of these models) in those patients not receiving OAC ranges from 0.63 to 0.70,4

The inadequacy of existing schema is perhaps most obvious among those patients considered at ‘moderate risk’ of stroke. In the article by Brusch et al,5 the CHADS2 classified the largest cohort of participants as moderate risk (nearly 60%, versus 35% who were classified as ‘high risk’), compared with most participants being classified at ‘high risk’ by the American College of Chest Physicians (96% to 97%), the van Walraven (99.2%), and AF Investigators (85.1%) schemes; the c statistics for the various schema in these subjects—all of whom were receiving warfarin or ximelagatran—ranged from 0.53 to 0.65. Given that most guidelines1–3 recommend either aspirin or OAC for ‘moderate risk’ subjects, having a risk stratification scheme that classifies most of a particular patient cohort into the ‘moderate risk’ category may confuse clinicians even more, on what is the best treatment for an individual patient.

The reasons for the poor categorization and predictive capacity of stroke risk schema have been explored in detail. AF commonly associates with numerous risk factors, many of which also directly enhance the risk of stroke. Many risk stratification schema try to incorporate these in their assessment, but coronary, carotid and peripheral vascular disease, which by their virtue are still important risk factors for stroke, are often overlooked in clinical trial cohorts5 and have even been cited as a ‘less validated or weaker risk factor’ in some guidelines.2 This may partly explain the underperformance of some risk stratification schema. The NICE schema4 categorizes ‘high risk’ subjects as those AF patients with stroke or thromboembolism, or those aged over 75 years with either vascular disease, diabetes or hypertension, or those with clinical evidence of valve disease, heart failure, or impaired left ventricular function on echocardiography. Of note, Baruch et al6 have not assessed the performance of the NICE schema in their analysis, which would be of interest.

Given the difficulties in the application of these risk stratification models, perhaps thromboprophylaxis in AF should be viewed from an alternative perspective. Indeed, given the strong evidence base for OAC in reducing both morbidity and mortality in AF, maybe a shift toward justifying why not to offer anticoagulation to these patients should be encouraged. This was evident in the recent Birmingham Atrial Fibrillation Treatment of the Aged Study (BAFTA) clinical trial, where OAC (international normalized ratio, 2 to 3) was superior to aspirin 75 mg daily even in an elderly (age ≥75 years) population with AF in the primary care setting, with no difference in bleeding rates between the 2 treatment arms—suggesting that more widespread use of OAC therapy for stroke prevention in AF should be supported, ‘unless there are contraindications or where the benefits are not worth the inconvenience’ of such therapy.6

Disclosures

None.

Jaspal S. Taggar, MRCP
Timothy Watson, MRCP
Gregory Y.H. Lip, MD
University Department of Medicine, City Hospital
Birmingham, UK


(Stroke. 2008;39:e24-e25.)
© 2008 American Heart Association, Inc.

Stroke is available at http://stroke.ahajournals.org

DOI: 10.1161/STROKEAHA.107.502369

e24


Can Patients With Atrial Fibrillation Be Optimally Risk Stratified for Stroke and Thromboembolism?

Jaspal S. Taggar, Timothy Watson and Gregory Y.H. Lip

Stroke. 2008;39:e24-e25; originally published online December 27, 2007;
doi: 10.1161/STROKEAHA.107.502369

Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2007 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/39/2/e24

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org//subscriptions/